Compare IQIYI Inc - ADR (IQ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Mesoblast Limited — how do they compare? IQIYI Inc - ADR trades at $1.02 (market cap $974.67M), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is more actively traded (239,027 versus 4,964,108). Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Mesoblast Limited for 15 Days on average.
| IQ | MESO | |
|---|---|---|
Market Cap | $974.67M | $1.75B |
Volume | 4,964,108 | 239,027 |
Sector | Media | Health |
52-Week High | $2.35 | $20.96 |
52-Week Low | $0.86 | $13.19 |
Typical Hold Time | 55 Days | 15 Days |
Enterprise Value | $2.47B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
iQIYI (IQ) trades at $1.02, up 0.49% with bearish technical signals despite recent earnings beats. The company faces revenue contraction to $27.29B in 2025 and negative net margins (-3.22%), though valuation ratios like P/S (0.25) and P/B (0.52) appear attractive. Recent news highlights AI-driven content initiatives, including the successful 'The Ferry Man' series, as management pivots to offset streaming declines.
Outlook remains challenged by sustained losses and competitive pressures, but analyst consensus leans bullish (50% Buy ratings). Key risks include execution on AI content monetization and Chinese regulatory environment. The stock's deep value profile offers speculative appeal if operational turnaround materializes.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
